207 related articles for article (PubMed ID: 23605952)
21. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
[No Abstract] [Full Text] [Related]
22. Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy.
Erba HP
Leuk Res; 2015 Feb; 39(2):183-91. PubMed ID: 25577399
[TBL] [Abstract][Full Text] [Related]
23. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
24. A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia.
Schliemann C; Gerss J; Wiebe S; Mikesch JH; Knoblauch N; Sauer T; Angenendt L; Kewitz T; Urban M; Butterfass-Bahloul T; Edemir S; Vehring K; Müller-Tidow C; Berdel WE; Krug U
PLoS One; 2016; 11(10):e0164499. PubMed ID: 27716819
[TBL] [Abstract][Full Text] [Related]
25. A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Copland M; Ariti C; Thomas IF; Upton L; Sydenham M; Mehta P; Islam S; Kjeldsen L; Burnett AK; Hills RK; Russell N; Dennis M;
Br J Haematol; 2024 Mar; 204(3):871-876. PubMed ID: 38016651
[TBL] [Abstract][Full Text] [Related]
26. Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).
Keizer RJ; Zandvliet AS; Beijnen JH; Schellens JH; Huitema AD
Invest New Drugs; 2012 Aug; 30(4):1519-30. PubMed ID: 21626115
[TBL] [Abstract][Full Text] [Related]
27. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).
Robles C; Kim KM; Oken MM; Bennett JM; Letendre L; Wiernik PH; O'Connell MJ; Cassileth PA
Leukemia; 2000 Aug; 14(8):1349-53. PubMed ID: 10942228
[TBL] [Abstract][Full Text] [Related]
28. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Kadia TM; Faderl S; Ravandi F; Jabbour E; Garcia-Manero G; Borthakur G; Ferrajoli A; Konopleva M; Burger J; Huang X; Wang X; Pierce S; Brandt M; Feliu J; Cortes J; Kantarjian H
Cancer; 2015 Jul; 121(14):2375-82. PubMed ID: 25809968
[TBL] [Abstract][Full Text] [Related]
29. A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy.
Solem CT; Bell TJ; Kwon Y; Cappelleri JC; Johnson C; Bhattacharyya H; Hoang CJ; Cortes JE
Cancer; 2020 Oct; 126(19):4315-4321. PubMed ID: 32697335
[TBL] [Abstract][Full Text] [Related]
30. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Ravandi F; Ritchie EK; Sayar H; Lancet JE; Craig MD; Vey N; Strickland SA; Schiller GJ; Jabbour E; Erba HP; Pigneux A; Horst HA; Recher C; Klimek VM; Cortes J; Roboz GJ; Odenike O; Thomas X; Havelange V; Maertens J; Derigs HG; Heuser M; Damon L; Powell BL; Gaidano G; Carella AM; Wei A; Hogge D; Craig AR; Fox JA; Ward R; Smith JA; Acton G; Mehta C; Stuart RK; Kantarjian HM
Lancet Oncol; 2015 Sep; 16(9):1025-1036. PubMed ID: 26234174
[TBL] [Abstract][Full Text] [Related]
31. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial.
Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE
Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279
[TBL] [Abstract][Full Text] [Related]
32. FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.
Norsworthy KJ; By K; Subramaniam S; Zhuang L; Del Valle PL; Przepiorka D; Shen YL; Sheth CM; Liu C; Leong R; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Oct; 25(20):6021-6025. PubMed ID: 31064779
[TBL] [Abstract][Full Text] [Related]
33. Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.
Gully CP; Zhang F; Chen J; Yeung JA; Velazquez-Torres G; Wang E; Yeung SC; Lee MH
Mol Cancer; 2010 Feb; 9():42. PubMed ID: 20175926
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
[TBL] [Abstract][Full Text] [Related]
35. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.
Grundy M; Seedhouse C; Shang S; Richardson J; Russell N; Pallis M
Mol Cancer Ther; 2010 Mar; 9(3):661-72. PubMed ID: 20159992
[TBL] [Abstract][Full Text] [Related]
36. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Röllig C; Serve H; Hüttmann A; Noppeney R; Müller-Tidow C; Krug U; Baldus CD; Brandts CH; Kunzmann V; Einsele H; Krämer A; Schäfer-Eckart K; Neubauer A; Burchert A; Giagounidis A; Krause SW; Mackensen A; Aulitzky W; Herbst R; Hänel M; Kiani A; Frickhofen N; Kullmer J; Kaiser U; Link H; Geer T; Reichle A; Junghanß C; Repp R; Heits F; Dürk H; Hase J; Klut IM; Illmer T; Bornhäuser M; Schaich M; Parmentier S; Görner M; Thiede C; von Bonin M; Schetelig J; Kramer M; Berdel WE; Ehninger G;
Lancet Oncol; 2015 Dec; 16(16):1691-9. PubMed ID: 26549589
[TBL] [Abstract][Full Text] [Related]
37. Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.
Relias V; McBride A; Newman MJ; Paul S; Saneeymehri S; Stanislaus G; Tobin J; Hoang CJ; Ryan JC; Galinsky I
J Oncol Pharm Pract; 2021 Apr; 27(3):658-672. PubMed ID: 33215562
[TBL] [Abstract][Full Text] [Related]
38. Efficacy outcomes in the treatment of older or medically unfit patients with acute myeloid leukaemia: A systematic review and meta-analysis.
Stone A; Zukerman T; Flaishon L; Yakar RB; Rowe JM
Leuk Res; 2019 Jul; 82():36-42. PubMed ID: 31152922
[TBL] [Abstract][Full Text] [Related]
39. All-trans retinoic acid in association with low dose cytosine arabinoside in the treatment of acute myeoid leukemia in elderly patients.
Di Febo A; Laurenti L; Falcucci P; Tosti ME; Fianchi L; Pagano L; Leone G
Am J Ther; 2007; 14(4):351-5. PubMed ID: 17667210
[TBL] [Abstract][Full Text] [Related]
40. A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Berdel AF; Koch R; Gerss J; Hentrich M; Peceny R; Bartscht T; Steffen B; Bischoff M; Spiekermann K; Angenendt L; Mikesch JH; Kewitz T; Butterfass-Bahloul T; Serve H; Lenz G; Berdel WE; Krug U; Schliemann C
Ann Hematol; 2023 Jan; 102(1):63-72. PubMed ID: 36399194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
